Target enrolment achieved in CAVATAK™
USA Phase 2 melanoma trial with excellent
interim results.
Target enrolment achieved in the US CALM trial with 54th
patient injected with
CAVATAK.
Rapid enrolment reflects high interest from oncologists at leading US cancer
centres.
Latest results show 14 of 40 (35%) evaluable patients reaching the six month
irPFS target.
Further promising one year survival data
with 12 of first 20 patients alive at
one year (60%).
